ACTRN12613000310763已完成2 期
Acetyl Cysteine for the Treatment of Obsessive Compulsive Disorder (OCD)
The Melbourne Clinic0 个研究点目标入组 80 人开始时间: 2013年3月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Fulfil DSM-IV TR diagnostic criteria for OCD
- •Self reported OCD will require a diagnosis from a physician
- •Score 16+ on the Y-BOCS at the time of recruitment
- •No other treatment, or be on stable treatment i.e. minimum 4 weeks of treatment or minimum of 12 weeks if a new treatment (e.g. SSRI, CBT)
- •Female participants of child bearing age or sexually active are required to be using effective contraception
排除标准
- •Known or suspected serious medical disorder i.e. cancer, organ failure
- •Patients undergoing current psychological programs for their OCD (a four week wash out period will be required for eligibility)
- •Bipolar I, schizophrenia, epilepsy
- •Gastrointestinal ulcers
- •Pregnancy or breastfeeding
- •History of hypersensitivity or intolerance to NAC
- •Patients taking 100 micrograms of selenium or 500 IU of vitamin E
研究者
相似试验
已完成
3 期
acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trialMental Health - Other mental health disordersObsessive-Compulsive DisorderACTRN12616000847415The University of Melbourne98
已完成
2 期
Adjuvant N Acetylcysteine for Post Traumatuic Stress DisorderACTRN12618001784202Austin Health105
尚未招募
2 期
Therapeutic effects of N-AcetylCysteine in Bipolar Mania as assessed by Serum Glutathione levelsCTRI/2023/08/056207Central Institute of Psychiatry
进行中（未招募）
1 期
Die antidementive Therapie mit Acetylcholinesteraseinhibitoren: Untersuchung von Plasmakonzentrationen, Arzneimittelinteraktionen und Therapieeffekt in Abhängigkeit von genetischen PolymorphismeAnhand der vorliegenden Studie soll untersucht werden, ob genetische Polymorphismen im CYP2D6-, im MDR1- oder im ACHE Gen mit sub- bzw. supratherapeutischen Wirkstoffspiegeln im Plasma, mit relevanten Arzneimittelinteraktionen und/oder mit Unterschieden im klinischen Anprechen auf die antidementiv wirksamen Substanzen Donepezil Hydrochlorid, Galantamin Hydrobromid und Rivastigmin in Verbindung stehen.EUCTR2008-005472-27-ATMedizinische Universität Innsbruck300
已完成
不适用
acetylcysteine as a Preventive Measure for Contrast Induced Nephropathy in Intensive Care Patients with Renal InsufficiencyRenal insufficiencyUrological and Genital DiseasesISRCTN43635237Academic Medical Centre (AMC) (Netherlands)246